Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

ENSAT Stage I Adrenal Cortex Carcinoma 1

Interventions

Specimen Handling 321Magnetic Resonance Spectroscopy 276pembrolizumab 265Carboplatin 190Cyclophosphamide 184Biopsy 179Cisplatin 163Paclitaxel 137Gemcitabine 137Bevacizumab 124fludarabine 119Nivolumab 117Radiotherapy 114Oxaliplatin 92Docetaxel 90venetoclax 89Fluorouracil 88Capecitabine 88Dexamethasone 86Pemetrexed 75Drug Therapy 73Rituximab 72Leucovorin 71durvalumab 70Blood Specimen Collection 69Radiosurgery 68atezolizumab 67Standard of Care 67Doxorubicin 65Radiation 63

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ethane × 90 days × Clear all
NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

M.D. Anderson Cancer Center

Phase 3 Recruiting
240 enrolled

ENSAT Stage I Adrenal Cortex Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡